Advertisement
Product › Details
TheraPEG™ Factor VIII
Next higher product group | coagulation factor VIII (INN s) | |
Status | 2012-09-10 development existent | |
Organisation | Pro Bono Bio Group plc (PCC) | |
Organisation 2 | PolyTherics Ltd. | |
Group | Abzena (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for haemostat_o
- [1] Hemab ApS. (2/21/23). "Press Release: Hemab Therapeutics Announces $135M Series B Financing to Advance First Prophylactic Treatments for Underserved Bleeding and Thrombotic Disorders". Copenhagen & Boston, MA....
- [2] Bayer AG. (8/30/18). "Press Release: Bayer Receives US Approval for Modern Hemophilia A Treatment Jivi with a Step-wise Prophylaxis Dosing Regimen [Not intended for U.S. and UK Media]". Berlin....
- [3] Roche. (11/16/17). "Press Release: FDA Approves Roche’s Hemlibra (emicizumab-kxwh) for Haemophilia A with Inhibitors". Basel....
- [4] Bayer AG. (9/7/17). "Press Release: Bayer Submits Marketing Authorization Application for BAY94-9027 for the Treatment of Hemophilia A in the EU [Not intended for U.S. and UK Media]". Berlin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top